2024
Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawal
2023
Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger study
2013
High rates of police detention among recently released HIV-infected prisoners in Ukraine: Implications for health outcomes
Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: Implications for health outcomes. Drug And Alcohol Dependence 2013, 133: 154-160. PMID: 23769160, PMCID: PMC3786010, DOI: 10.1016/j.drugalcdep.2013.05.018.Peer-Reviewed Original ResearchConceptsOpioid substitution therapyAntiretroviral therapyHIV transmissionHIV epidemicHigh-risk injection practicesSignificant independent correlatesMedication interruptionOST treatmentART prescriptionAdverse eventsSubstitution therapyIndependent correlatesWithdrawal symptomsMale genderEssential medicationsInjection practicesHealth outcomesLogistic regressionHIVPublic healthTherapyHigh rateHealthCorrelatesParticipants
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLXLack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market
Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market. The American Journal Of Drug And Alcohol Abuse 2009, 35: 68-72. PMID: 19212931, PMCID: PMC2791788, DOI: 10.1080/00952990802585406.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid withdrawal symptomsSyringe sharingWithdrawal symptomsSnowball recruitment techniquesLogistic regression analysisDiversion of buprenorphineLack of reductionEvidence-based approachPrimary outcomeBuprenorphine injectionOnly symptomBenzodiazepine useBenzodiazepine injectionStomach painBuprenorphineInjection doseRisk behaviorsSymptomsNaloxoneInjectionRegression analysisNLXDaily amountDose
1999
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
Altice F, Friedland G, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999, 13: 957-962. PMID: 10371177, DOI: 10.1097/00002030-199905280-00012.Peer-Reviewed Original ResearchConceptsPharmacokinetic interactionsOpiate withdrawalMethadone levelsWithdrawal symptomsChronic methadone maintenance therapyNon-nucleoside reverse transcriptase inhibitorSubstance abuseInitiation of therapyMethadone maintenance therapyOpiate withdrawal symptomsRetrospective chart reviewSignificant pharmacokinetic interactionsInjection drug usersReverse transcriptase inhibitorHIV therapeutic agentsAntiretroviral therapyMaintenance therapyMethadone doseChart reviewHIV diseaseHIV infectionIncreased doseTranscriptase inhibitorTherapeutic benefitPatients